ArticleCancer research2023

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.

Mandy Lawson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.